PHARMA NEWS

  • Pfizer has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its biologics ...

  • Eli Lilly and Company has completed a $90-million expansion of its Biotechnology Center in San Diego, California. The facility ...

  • Baxter International has signed an agreement with Dorizoe Lifesciences, a contract research and development organization, ...

  • Pfizer and Basilea Pharmaceutica, a Swiss biopharmaceutical company specializing in anti-infective and oncological medicines, ...

  • Novartis, Amgen Lead Pipeline News

    A roundup of the latest pipeline news, including from the pharmaceutical majors, featuring news from Novartis and Amgen ...

  • A roundup of the latest drug approval news, including from the pharmaceutical majors, featuring news from Novartis, Teva, ...

  • Merck KGaA’s corporate venture arm has created iOnctura, an immuno-oncology spin-out company based in Geneva, Switzerland. ...

  • Takeda Pharmaceutical Company has completed the construction of a new EUR-100 million ($111-million) solid-dosage manufacturing ...

  • Hospira, a Pfizer company, is voluntarily recalling multiple lots of sodium bicarbonate for injection and other products ...

  • Johnson & Johnson has completed its previously announced acquisition of Actelion, a Swiss pharmaceutical company specializing ...

  • Bristol-Myers Squibb and SK Biotek Co., Ltd. have signed a definitive purchase agreement to sell Bristol-Myers Squibb’s ...

  • As the UK moves into negotiations with the European Union, a new alliance, the Brexit Health Alliance, has been formed as ...

  • Dr. Reddy’s Labpratories is voluntarily recalling 765,018 cartons of its Zenatane (isotretinoin) capsules, an acne medicine, ...

  • Sawai Pharmaceutical, a Japanese generic pharmaceuticals manufacturer, has completed its previously announced acquisition ...

  • A roundup of the latest pipeline news, including from the pharmaceutical majors, featuring news from Amgen, Allergan, ...

  • The US Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated ...

  • Taiho Pharmaceutical, part of the Japanese pharmaceutical company, Otsuka. broke ground for the construction of a new building ...

  • Basilea Pharmaceutica, a Basel, Switzerland-based pharmaceutical company, has been awarded $54.8 million for two additional ...

  • Innate Pharma SA, a biopharmaceutical company, has signed an agreement with Novo Nordisk  granting Innate Pharma full worldwide ...

  • AbbVie has formed a collaboration with Principia Biopharma, a private, clinical-stage biopharmaceutical company, for the ...

  • Bristol-Myers Squibb is voluntarily recalling one lot of the anticoagulant, Eliquis (apixaban), in 5-mg tablets to the consumer ...

  • Boehringer Ingelheim has formed BI X as an independent subsidiary to focus on digital solutions in healthcare from idea ...

  • AstraZeneca has formed an agreement with Grünenthal, a  pharmaceutical company specializing in treatments for pain, gout ...

  • Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its iNova Pharmaceuticals business to ...

  • A roundup of the latest drug approval news, including from the pharmaceutical majors, featuring news from Biogen, Bristol-Myers ...

  • A roundup of the latest pipeline news, including from the pharmaceutical majors, featuring news from Amgen and Pfizer ...

  • Merck KGaA has formed a new strategic collaboration F-star, a Cambridge, UK-based biopharmaceutical company,, for the development ...

  • Bristol-Myers Squibb has formed separate research pacts with Novartis, Qiagen, and Seattle Genetics for oncology. In ...

  • Novartis has formed a collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient ...

  • Senator Chuck Grassley (R-Iowa), chairman of the US Senate Judiciary Committee, is pressing for further information regarding ...

  • John T. Hendrickson, chief executive officer (CEO) of Perrigo, announced his forthcoming retirement from the company, 14 ...

  • Takeda Pharmaceutical Company Limited has broken ground for a new production facility at its existing Grange Castle site ...

  • Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health report that the US Food and Drug Administration (FDA) has acknowledged ...

  • Roche, in consultation with the Therapeutic Goods Administration (TGA), the national regulatory authority in Australia, ...

  • MSD, known as Merck & Co., Inc., in the U.S. and Canada, plans to invest EUR 280 million ($313 million) over the next ...

  • Pierre Fabre, a French pharmaceutical company, has agreed to acquire several assets from Igenica Biotherapeutics, a Burlingame, ...

  • Protagonist Therapeutics, a Newark, California-based clinical-stage biopharmaceutical company, has formed a worldwide license ...

  • Merck & Co. Inc. has entered into an exclusive worldwide license agreement with Teijin Pharma for the development, manufacture, ...

  • BMS, Advaxis Form Clinical Pact

    Advaxis, a biopharmaceutical company developing immunotherapies, and Bristol-Myers Squibb have formed a clinical development ...

  • BMS, Array BioPharma Partner

    Array BioPharma, a Boulder, Colorado-based biopharmaceutical company developing small-molecule anti-cancer therapies, and ...

  • A roundup of the latest drug approval news, including from the pharmaceutical majors, featuring news from Novartis, Roche, ...

  • A roundup of the latest pipeline news, including from the pharmaceutical majors, featuring news from Pfizer, Novartis, ...

  • Alexion Pharmaceuticals, a New Haven, Connecticut-based biopharmaceutical company, has made further changes to its executive ...

  • GlaxoSmithKline (GSK) has issued a voluntary Class II recall of 562,883 Ventolin HFA (albuterol sulfate) Inhalation, 90 ...

  • Sun Pharma Advanced Research Company Limited (SPARC), part of Sun Pharmaceutical Industries, has received a Complete Response ...

  • Granules India Ltd., a pharmaceutical manufacturing company will invest $35 million into its wholly owned subsidiary, Granules ...

  • Aduro Biotech, a biopharmaceutical company witht immunotherapy technologies, has expanded its clinical collaboration with ...

  • AstraZeneca has entered into an agreement with Recordati S.p.A, an Italian pharmaceutical company, for the commercial rights ...

  • A roundup of the latest drug approval news, including from the pharmaceutical majors, featuring news, with news from ...

  • Novartis plans to add 350 new positions for biological development and manufacturing in Switzerland while cutting approximately ...

  • Biogen has completed an asset purchase of Phase III candidate, Cirara (intravenous glyburide), a drug to treat a severe ...

  • A roundup of the latest drug pipeline news, including from the pharmaceutical majors, featuring news from Amgen, AstraZeneca, ...

  • Bristol-Myers Squibb (BMS) and Calithera Biosciences, a clinical-stage biotechnology company fdeveloping small-molecule ...

  • Merck KGaA announced that it will remain at its headquarters site in Darmstadt, Germany, and announced a plan to upgrade ...

  • Boehringer Ingelheim and Peking University (PKU) in China have formed a strategic partnership with the aim of jointly advancing ...

  • Boehringer Ingelheim has inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park in ...

  • Novartis has exercised its option for an exclusive license with Conatus Pharmaceuticals, a biopharmaceutical company, for ...

  • A roundup of the latest drug approval news, including from the pharmaceutical majors, featuring news, with news from ...

  • Lupin Limited, a Mumbai-based pharmaceutical company, has launched, through a partnership with Eli Lilly and Company, Lilly's ...

  • Teva Pharmaceutical Industries reports that it plans to sell certain non-core assets, including its global women’s health ...

  • A roundup of the latest drug pipeline news, including from the pharmaceutical majors, featuring news from AstraZeneca ...

  • Pfizer has formed an exclusive, global collaboration and license agreement, worth up to $545 million, with Richmond, California-based ...

  • Levena Biopharma Co., Ltd., a subsidiary of San Diego-based Sorrento Therapeutics, a clinical-stage biopharmaceutical company, ...

  • Sandoz, the generics arm of Novartis, has formed a development and commercialization agreement, worth up to $293 million, ...

  • Merck & Co. Inc. has formed a clinical-trial collaboration agreement with Array BioPharma, a pharmaceutical company developing ...

  • Sanofi has formed a strategic research collaboration and license option agreement, worth up to $272 million, for bispecific ...

  • Takeda Pharmaceutical Company Limited has cancelled its planned launch in Japan of Vaxem Hib, a conjugate vaccine to prevent ...

  • Takeda Pharmaceutical Company Limited and GammaDelta Therapeutics Ltd, a portfolio biopharmaceutical company of the investmenty ...

  • Amgen has formed a research collaboration for intracellular biologics with Elasmogen Ltd, an Aberdeen, Scotland-based biopharmaceutical ...

  • AstraZeneca has formed a strategic collaboration with Pieris Pharmaceuticals, a Boston-headquartered clinical-stage biopharmaceutical ...

  • Julphar Gulf Pharmaceutical Industries, a Ras Al Khaimah, United Arab Emirates-headquartered generic pharmaceutical company, ...

  • Dr. Reddy’s Laboratories has received a Form 483 with 11 observations from the US Food and Drug Administration (FDA) for ...

  • Due to an expected shortage of Sanofi’s YF-VAX yellow fever vaccine because of a manufacturing issue with Sanofi Pasteur, ...

  • Novartis in CAR-T Patent Deal

    Novartis has entered into a non-exclusive license agreement with Celyad, a Mont-Saint-Guibert, Belgium-headquartered biopharmaceutical ...

  • Lupin, a Mumbai, India-headquartered generic pharmaceutical company, has received a Form 483 from the US Food and Drug Administration ...

  • GlaxoSmithKline (GSK) is investing $139 million in its biopharmaceutical manufacturing site in Rockville, Maryland to expand ...

  • Shire has entered into an agreement with Parion Sciences, a Durham, North Carolina-headquartered development-stage biopharmaceutical ...

  • Otsuka Pharmaceutical has expanded a collaboration with Akebia Therapeutics, Cambridge, Massachusetts-headquartered biopharmaceutical ...

  • Daiichi Sankyo is making an initial Japanese yen 15 billion ($135 million) investment into three of its manufacturing plants ...

  • Allergan has completed the previously announced  acquisition of Zeltiq Aesthetics, a Pleasanton, California-headquartered ...

  • Divi’s Laboratories has received a Warning Letter from the US Food and Drug Administration (FDA) for its active pharmaceutical ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from AstraZeneca, Bayer, ...

  • The US Senate Committee on Health, Education, Labor & Pensions has voted to advance the nomination of Scott Gottlieb, MD, ...

  • The heads of research of a number of major pharmaceutical companies, including Pfizer, Roche, Sanofi, Novartis, and GlaxoSmithKline ...

  • As part of its first quarter earnings, Novartis reports that it is on track with productivity initiatives created with the ...

  • The US Supreme Court heard oral arguments concerning notification requirements by a b iosimilar developer to an innovator ...

  • Sawai Pharmaceutical, an Osaka, Japan-headquartered generic pharmaceuticals manufacturer, has agreed to acquire the US generics ...

  • Fresenius Kabi, a specialty and generic pharmaceuticals company and a subsidiary of Fresenius SE & Co. KGaA, a Bad Homburg, ...

  • BMS Partners in Lung Cancer Therapy

    Bristol-Myers Squibb (BMS) has partnered with Transgene, an Illkirch Graffenstaden Cedex, France-headquartered biopharmaceutical ...

  • Novartis, Amgen Expand Migraine Pact

    Novartis and Amgen have expanded a commercialization agreement they formed in September 2015 for Amgen’s erenumab, a fully ...

  • Teva Pharmaceutical Industries has simultaneously launched AirDuo RespiClick (fluticasone propionate and salmeterol) inhalation ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • Sun Pharmaceutical Industries, a Mumbai, India-headquartered specialty generic pharmaceutical company, has received a Form ...

  • Aurobindo, a Hyderabad, India-headquartered generics and active pharmaceutical ingredients manufacturer, has received a ...

  • Merck & Co. has entered into a clinical-trial collaboration with Atara Biotherapeutics, a South San Francisco-based biopharmaceutical ...

  • Samsung Bioepis, an Incheon, South Korea-headquartered biopharmaceutical company that is a joint venture between Samsung ...

  • Novartis Leads Pipeline News

    A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • Novartis has entered into a clinical-trial agreement with Allergan to conduct a Phase IIb study involving the combination ...

  • The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Eli Lilly and Company and its partner, ...

  • Merck & Co. has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its supplemental ...

  • Indoco Remedies, a Mumbai, India-headquartered active pharmaceutical ingredient (API) and finished dosage form manufacturer, ...

  • Roche Leads Drug Approval News

    A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Roche and Neurocrine ...

  • Bristol-Myers Squibb (BMS) has entered into two separate agreements, respectively with Roche and Biogen, to license two ...

  • Mylan has received a Warning Letter from the US Food and Drug Administration (FDA) related to data-integrity issues for ...

  • Teva Pharmaceutical Industries has received a Warning Letter from the US Food and Drug Administration (FDA) for the company’s ...

  • Axovant Sciences, a Bermuda-based clinical-stage biopharmaceutical company focused on treating dementia, has named David ...

  • Akorn, a Lake Forest, Illinois-headquartered specialty generic pharmaceutical company, has confirmed that it is currently ...

  • Zambon in Parkinson’s Disease Deal

    Zambon, a Bresso, Italy-headquartered pharmaceutical company focused on central nervous system (CNS) therapeutics, has entered ...

  • Takeda in GI Drug Pact

    Takeda Pharmaceutical has entered into a strategic collaboration with NuBiyota, a Teaneck, New Jersey-based biological product ...

  • GlaxoSmithline (GSK) has begun construction on a new meningococcal B vaccine manufacturing plant in Marburg, Germany, in ...

  • Stada Arzneimittel AG, a Bad Vilbel, Germany-headquartered pharmaceutical company, signed an investor agreement with Bain ...

  • Mylan plans to close a manufacturing plant in Decatur, Illinois that it gained as part of its $7.2-billion acquisition of ...

  • Meridian Medical Technologies, a Pfizer company and Mylan’s manufacturing partner for EpiPen Auto-Injector, has expanded ...

  • Perrigo has completed the previously announced divestiture of its rights to the royalty stream from global net sales of ...

  • Astellas Pharma has agreed to acquire Ogeda, a Gosselies, Belgium-headquartered privately owned clinical-stage drug discovery ...

  • Astellas Pharma has entered into an asset purchase agreement with LTL Pharma, a wholly-owned subsidiary of Japan Established ...

  • Eisai has entered into a license agreement with Meiji Seika Pharma, a Tokyo-headquartered pharmaceutical company, for the ...

  • Novartis In-Licenses Ophthalmic Drug

    Novartis has exercised an option to in-license a recombinant human lubricin (rh-Lubricin) protein for ophthalmic indications ...

  • Takeda Pharmaceutical has partnered with Finch Therapeutics, a Somerville, Masshachusetts-based privately held microbiome ...

  • Takeda Sells Seven Products to Teva

    Takeda Pharmaceutical plans to sell 7 additional long-listed products (off-patent brand-name drugs) in Japan to Teva Takeda ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from AstraZeneca, Merck ...

  • Merck KGaA has entered into a development agreement with Avillion, a UK-based company focused on increasing research and ...

  • Merck & Co. and Incyte Corporation, a Wilmington, Delaware-headquartered biopharmaceutical company, have expanded their ...

  • AstraZeneca has entered a strategic collaboration with Circassia Pharmaceuticals, an Oxford, UK-headquartered respiratory ...

  • Bristol-Myers Squibb (BMS) and CytomX Therapeutics, a South San Francisco, California-headquartered biopharmaceutical company ...

  • The US Food and Drug Administration (FDA) has issued an Establishment Inspection Report (EIR) to Alkem Laboratories, a Mumbai, ...

  • The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to AstraZeneca following an inspection ...

  • GlaxoSmithKline (GSK) has issued a voluntary Class II recall of 593,088 inhalers of Ventolin HFA (albuterol sulfate) inhalation ...

  • The Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPT) has ruled in favor of Biogen in a ...

  • Pharmaceutical majors Roche, Sanofi, and Teva Pharmaceutical Industries have gained approval from the US Food and Drug Administration ...

  • Mylan has issued a voluntary Class II recall of 2,428,689 bottles and 1,527 cartons of atorvastatin calcium tablets, the ...

  • Amgen has received marketing authorization from the European Commission (EC) for Amgevita (adalimumab), a biosimilar to ...

  • Part of the special news roundup of DCAT member companies for the DCAT Week 17 Special Edition of DCAT Value Chain Insights ...

  • Part of the special news roundup of DCAT member companies for the DCAT Week 17 Special Edition of DCAT Value Chain Insights ...

  • Part of the special news roundup of DCAT member companies for the DCAT Week 17 Special Edition of DCAT Value Chain Insights ...

  • Lumis Global Pharmaceuticals, a Wuhan, China-based manufacturer of active pharmaceutical ingredients (APIs), has received ...

  • Badrivishal Chemicals & Pharmaceuticals, a Talegaon Dabhade, India-headquartered manufacturer of active pharmaceutical ingredients ...

  • The US Food and Drug Administration has recently issued Warning Letters to two India-based and one China-based active pharmaceutical ...

  • Sun Pharmaceutical Industries, a Mumbai, India-headquartered specialty generic pharmaceutical company, has been informed ...

  • Mayne Buys Transdermal Drug Rights

    Mayne Pharma, a Salisbury South, Australia-headquartered contract development and manufacturing organization and drug delivery ...

  • The Food and Drug Administration (FDA) is considering establishing a new Office of Patient Affairs to enhance future patient ...

  • Pfizer has issued a voluntary Class III recall for 582,165 vials of the gastrointestinal drug, Protonix (pantoprazole sodium) ...

  • Allergan in CRISPR Eye-Drug Pact

    Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, has entered into a strategic research ...

  • Takeda Partners on Biotech Venture

    Takeda Pharmaceutical has partnered with Innovation Network Corporation of Japan (INCJ), a Tokyo-headquartered public-private ...

  • Daiichi Sankyo in Pain-Drug Deal

    Daiichi Sankyo has entered into a drug discovery and licensing agreement with Heptares Therapeutics Limited, a Hertfordshire, ...

  • Amo Pharma Partners in Rare Diseases

    Amo Pharma, a London-based privately held biopharmaceutical company, has entered into a collaboration agreement with Ranedis ...

  • Megafine Pharma, a Mumbai, India-headquartered manufacturer of active pharmaceutical ingredients (APIs) and advanced intermediates, ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Novartis and Pfizer. ...

  • The Pharmaceutical Inspection Co-operation Scheme (PIC/S), a non-binding, informal co-operative arrangement between regulatory ...

  • Mylan has agreed to the terms of a global settlement with Roche and its subsidiary, Genentech, in relation to patents for ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • Dr. Reddys Laboratories is addressing a violations report issued by the US Food and Drug Administration (FDA) for Dr. Reddys ...

  • The US Food and Drug Administration (FDA) has issued a Warning Letter dated February 17, 2017 to Morton Grove Pharmaceuticals, ...

  • President Donald Trump has announced his intent to nominate Scott Gottlieb, MD, as Commissioner of Food and Drugs at the ...

  • Apotex Inc., a Weston, Florida-headquartered, Canadian-owned generic pharmaceutical company, plans to invest $184 million ...

  • BeiGene, a Beijing, China-based clinical-stage, research-based biotechnology company, has formed a joint venture with the ...

  • GlaxoSmithKline (GSK) has decided to transfer its manufacturing operation in Costa Rica after reviewing its global manufacturing ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • Vertex to Buy Cystic Fibrosis Drug

    Vertex Pharmaceuticals, a Boston, Massachusetts-headquartered biotechnology company, has agreed to acquire a cystic fibrosis ...

  • The Ministry of Health (MoH) of the Russian Federation has granted marketing authorization to Biocad, a St. Petersburg, ...

  • Sanofi and its vaccines global business unit, Sanofi Pasteur, have entered into an agreement with MedImmune, the global ...

  • Otsuka Pharmaceutical has agreed to acquire Neurovance, a Cambridge, Massachusetts-headquartered clinical-stage pharmaceutical ...

  • Merck KGaAs allergy business, Allergopharma, has opened a new EUR 42 million ($45 million) biopharmaceutical production ...

  • GlaxoSmithKline (GSK) has completed the previously announced divestiture of its anesthesia portfolio to Aspen Pharma, a ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Perrigo and Teva. ...

  • Ligand Pharmaceuticals, a San Diego-based biopharmaceutical company, has expanded its license with Sermonix Pharmaceuticals, ...

  • Astellas Pharma has entered into an exclusive worldwide license agreement with Affinivax, a Cambridge, Massachusetts-headquartered ...

  • Boehringer Ingelheim (BI) has formed a new multi-year collaboration with Vanderbilt University, based in Nashville, Tennessee, ...

  • Boehringer Ingelheim (BI) has invested EUR 52 million ($55 million) in a new building that recently opened at the Research ...

  • BMS Invests in Precision Medicine

    Bristol-Myers Squibb (BMS) has made an equity investment in and plans to form a research collaboration with Grail, a Menlo ...

  • Merck & Co. has reported that it is taking a $2.9-billion impairment charge on a hepatitis C drug candidate that the company ...

  • Novo Nordisk has appointed Doug Langa as senior vice president, head of North America Operations and president of Novo Nordisk ...

  • Eli Lilly and Company has completed its previously announced $960-million acquisition of CoLucid Pharmaceuticals, a Cambridge, ...

  • Perrigo has announced a global workforce reduction of 750 employees, or 14% of the companys global workforce, as part of ...

  • Endo International has reported $3.5-billion asset impairment charges in the fourth-quarter of 2016 relating to pricing ...

  • Endo Recalls One Lot of ED Drug

    Endo International plc, a specialty and generics drug company, reports that one of its operating companies, Endo Pharmaceuticals ...

  • Astellas Pharma has agreed to provide exclusive distribution and promotion rights in Japan to Kyowa Pharmaceutical Industry, ...

  • Baxter International has entered into a strategic partnership with ScinoPharm Taiwan, a Taiwan-based provider of process ...

  • Roche in Combo Cancer Therapy Deal

    Roche has formed a collaboration with Exelixis, a South San Francisco, California-headquartered biopharmaceutical company, ...

  • Bristol-Myers Squibb (BMS) has entered into a clinical development collaboration with, to evaluate Exelixis Cabometyx (cabozantinib), ...